RxDoctor Payments DataLook up a doctor →

Laura Frigyes, MD

Internal Medicine · Elkhorn, NENPI 1346355146

Payments from drug & device makers

$15,881in general payments, 2019–2025

Across 790 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$907
  • plus $5K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen119$2,796
AbbVie(2 entities)175$2,322
Novo Nordisk79$1,881
AstraZeneca31$1,536
Lilly USA, LLC100$1,269
Johnson & Johnson22$907
Pfizer49$647
Bayer27$559
Astellas Pharma US Inc13$296
Merck24$292
Otsuka America Pharmaceutical, Inc.12$261
Sanofi-aventis U.S. LLC7$257
Takeda Pharmaceuticals U.S.A., Inc.19$239
GSK9$202
Axsome Therapeutics, Inc.8$196
Medtronic(2 entities)4$186
Gilead4$173
Biohaven Pharmaceuticals, Inc.6$153
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$152
Phathom Pharmaceuticals, Inc.4$151
Ardelyx, Inc.2$139
Sumitomo Pharma America, Inc.2$131
Sanofi Pasteur Inc.7$130
Biohaven Pharmaceutical Holding Company Ltd.3$70
Upsher-smith Laboratories LLC4$67
Abbott3$66
Currax Pharmaceuticals LLC1$64
Exact Sciences3$56
Kowa Pharmaceuticals America, Inc.4$54
Amarin Pharma, Inc.3$49
Nalpropion Pharmaceuticals LLC3$45
Kyowa Kirin, Inc.3$43
Idorsia Pharmaceuticals US Inc2$38
Bristol Myers Squibb2$37
Impel Pharmaceuticals Inc.2$37
Boston Scientific2$34
Dermira, Inc.2$31
Xeris Pharmaceuticals, Inc.1$22
Supernus Pharmaceuticals, Inc.1$21
Genentech USA, Inc.1$20
Corium, LLC1$19
Scilex Pharmaceuticals Inc.1$19
Inspire Medical Systems, Inc.1$19
Corcept Therapeutics1$17
Zyla Life Sciences, Inc.1$16
Esperion Therapeutics, Inc.1$16
Dexcom, Inc.1$15
Ironwood Pharmaceuticals, Inc1$15
Jazz Pharmaceuticals Inc.1$14
Ultragenyx Pharmaceutical Inc.1$14
Teva Pharmaceuticals USA, Inc.1$14
Boehringer Ingelheim1$14
Regeneron Healthcare Solutions, Inc.1$13
Acadia Pharmaceuticals Inc1$12
Eisai Inc.1$12
Shire North American Group Inc1$11
Actelion Pharmaceuticals US, Inc.1$7
Organon1$7

How this compares

$15,881 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024
$148,996
Medicare patients
287
Services billed
3,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Elkhorn

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →